Regulation
Pulnovo Medical enrols first US patients in PULSE-LHD IDE trial
Pulnovo Medical has enrolled the first US patients in the PULSE-LHD IDE (Investigational Device Exemption) trial, evaluating PADN (pulmonary artery denervation) therapy for pulmonary hypertension with left heart disease. The trial represents a regulatory milestone for the device candidate in the US market.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network